Medications for opioid use disorder, commonly abbreviated as MOUD, are prescription drugs that reduce cravings, prevent withdrawal, and lower the risk of overdose death in people dependent on opioids. Three medications are currently approved for this purpose in the United States: methadone, buprenorphine, and naltrexone. Both methadone and buprenorphine cut all-cause and opioid-related mortality roughly in half among overdose survivors, making them among the most effective treatments in addiction medicine.1PubMed Central. Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study Despite that track record, a persistent gap exists between the number of people who could benefit and those who actually receive treatment.
The Three Medications and What They Do
Methadone is a full opioid agonist, meaning it activates the same brain receptors that heroin or fentanyl would, but does so in a slow, controlled way that prevents the euphoric rush and dangerous respiratory depression of street opioids. It has been used for opioid dependence since the 1960s and remains the most tightly regulated of the three options. In the U.S., methadone for opioid use disorder can only be dispensed through federally certified opioid treatment programs, which historically required patients to show up daily for observed dosing.2PubMed. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States
Buprenorphine is a partial opioid agonist. It stimulates the same receptors but with a ceiling effect: beyond a certain dose, its opioid activity levels off, which makes fatal overdose from buprenorphine alone extremely rare. Since 2000, federal legislation has allowed qualified clinicians to prescribe buprenorphine from ordinary medical offices, a flexibility that methadone has never had.3PubMed. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States The most common formulation combines buprenorphine with naloxone, a short-acting opioid blocker included to discourage misuse by injection.
Naltrexone takes the opposite approach. It is an opioid antagonist that blocks opioid receptors entirely, preventing any high if someone uses heroin or fentanyl while on it. An extended-release injectable form lasts about a month. The catch is that a patient must be fully detoxed from opioids before starting naltrexone, which creates a gap during which relapse risk is high. For that reason, research on mortality reduction with naltrexone is less robust than for the other two medications.
Mortality Reduction
The strongest argument for MOUD is its impact on survival. In a large cohort study of people who survived a nonfatal opioid overdose, those who received methadone maintenance had roughly half the risk of dying from any cause compared with those who received no medication. Buprenorphine showed a similar direction, cutting all-cause mortality by about a third.4PubMed Central. Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study A 2025 review in JAMA confirmed that both methadone and buprenorphine reduce the risks of overdose and all-cause mortality.5JAMA. Medications for Opioid Use Disorder, Opioid Withdrawal, and Opioid Overdose: A Review These are not modest effects. Few interventions in medicine halve a person’s risk of dying.
Methadone vs. Buprenorphine for Retention
One of the biggest practical questions in treatment is which medication keeps people engaged longer. Staying in treatment matters because stopping MOUD abruptly restores a person’s vulnerability to overdose, often at a time when their tolerance has dropped. Across multiple studies, methadone consistently outperforms buprenorphine on retention. In a multi-site trial, about three-quarters of methadone patients completed treatment compared with under half of buprenorphine patients.6PubMed Central. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial A large Canadian study found that buprenorphine/naloxone was associated with a higher risk of discontinuation at two years, with roughly 89% of buprenorphine initiators dropping out compared with about 82% on methadone.7JAMA. Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder
Dose matters enormously for both medications. The same multi-site trial found that when methadone doses reached at least 60 mg per day, the completion rate climbed to 80%. Buprenorphine retention improved with higher doses too, reaching 60% at doses of 30 to 32 mg per day.8PubMed Central. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial Underdosing is a common and correctable reason people leave treatment.
Retention numbers alone do not tell the whole story, though. Buprenorphine’s safety profile and the convenience of office-based prescribing mean that for many patients, it is the medication they will actually start and stay on, even if the statistical average favors methadone. Choosing between the two often comes down to individual circumstances: how severe the dependence is, whether a person can get to a methadone clinic daily, and their own treatment goals.
MOUD During Pregnancy
Opioid dependence during pregnancy poses risks to both the parent and the baby, and MOUD is the standard of care. Stopping opioids abruptly during pregnancy can trigger withdrawal that threatens the pregnancy itself. Both methadone and buprenorphine are considered safe and effective in this setting, but they are not identical in their neonatal effects.
In an early randomized trial comparing the two, newborns exposed to buprenorphine required significantly less morphine for withdrawal symptoms (about 1 mg on average, versus more than 10 mg for methadone-exposed newborns), spent fewer days in the hospital, and needed shorter treatment for neonatal abstinence syndrome.9PubMed Central. Neonatal abstinence syndrome after methadone or buprenorphine exposure A much larger observational study reinforced these findings: neonatal abstinence syndrome occurred in about 52% of buprenorphine-exposed infants versus 69% of those exposed to methadone. Buprenorphine was also associated with lower rates of preterm birth and low birth weight.10PubMed Central. Buprenorphine versus Methadone for Opioid Use Disorder in Pregnancy There was no meaningful difference in cesarean section rates or severe maternal complications between the two groups.
The Fentanyl Problem
Illicitly manufactured fentanyl has reshaped the landscape for MOUD in ways clinicians are still adapting to. Starting buprenorphine has always required that a patient be in at least mild opioid withdrawal first; otherwise, the medication can strip opioids from receptors and trigger “precipitated withdrawal,” a sudden, intensely unpleasant reaction. Fentanyl’s fat-soluble nature means it lingers in the body longer than heroin, making the timing of buprenorphine initiation harder to get right.
Research on how often precipitated withdrawal actually occurs with fentanyl has produced a wide range of estimates, from 1% to 16% of initiations depending on the study and setting.11PubMed. High-Dose Buprenorphine Treatment in the Setting of Fentanyl To work around this, clinicians have increasingly turned to low-dose initiation protocols, sometimes called “microdosing,” which layer small amounts of buprenorphine on top of ongoing opioid use over several days. In one study of outpatient low-dose initiation, about a third of attempts were considered successful, but only about one in five patients remained on buprenorphine at 28 days.12JAMA Network Open. Outpatient Low-Dose Initiation of Buprenorphine for People Using Fentanyl These numbers are sobering and reflect how much harder treatment initiation has become in the fentanyl era.
A newer complication involves veterinary tranquilizers showing up in the fentanyl supply. In Philadelphia, the emergence of medetomidine in street drugs coincided with a drop in MOUD uptake from emergency departments, falling from about 47% to 28% of eligible visits.13PubMed. Emergency Department Opioid Withdrawal Management Across the Alpha-2 Agonist Adulterated Fentanyl Era in Philadelphia, PA: A Multi-Site Study These adulterants create withdrawal symptoms that opioid medications alone cannot fully address, complicating an already difficult process.
How Long Should Treatment Last
One of the most contentious questions in opioid use disorder treatment is duration. Many patients and providers feel pressure to taper off MOUD after a period of stability, an impulse driven partly by the belief that staying on medication indefinitely means you are not “truly recovered.” The evidence pushes back hard against early discontinuation.
A study evaluating optimal duration found that the largest gain in six-year survival from additional time on MOUD occurred around the two-year mark. Statistically meaningful survival benefits continued through about four to five years of treatment. After that, the additional benefit of one more year was no longer significant.14PubMed Central. Evaluating the optimal duration of medication treatment for opioid use disorder This suggests that most patients benefit from staying on treatment for at least several years, and that the common practice of tapering people off after a few months of stability is premature.
Does Adding Counseling Improve Outcomes
The role of psychosocial therapy alongside MOUD is less clear-cut than you might expect. Intuitively, combining medication with counseling should yield better results, and some observational data supports this. One study found that receiving counseling alongside buprenorphine was associated with about a 20% lower chance of treatment discontinuation in the first six months.15PubMed Central. Psychosocial and behavioral therapy in conjunction with medication for opioid use disorder: Patterns, predictors, and association with buprenorphine treatment outcomes A retrospective study found counseling linked to a 21% lower likelihood of treatment discontinuation and 17% lower likelihood of poor medication continuity.16Journal of Substance Use and Addiction Treatment. Counseling as a complement to buprenorphine treatment for opioid use disorder: A retrospective observational study of patient outcomes
However, when researchers pooled data from four randomized trials, they found that adding structured behavioral therapy on top of standard medical management did not significantly increase opioid-free weeks or medication retention.17JAMA Network Open. Behavioral Therapy as an Adjunct to Buprenorphine Treatment for Opioid Use Disorder: A Secondary Analysis of 4 Randomized Clinical Trials Patients in the additional therapy group averaged about 7.2 opioid-free weeks out of 12, versus 7.0 without it. The practical takeaway is that counseling should be offered and encouraged, but making it a mandatory condition for receiving medication creates a barrier that may keep people away from the treatment that saves lives. Medication alone is better than no treatment.
Long-Acting Injectable Buprenorphine
One of the more promising developments in MOUD delivery is a long-acting injectable form of buprenorphine, given as a weekly or monthly shot under the skin. This eliminates the daily decision to take a pill and removes the possibility of diversion. In a randomized trial comparing depot (injectable) buprenorphine with daily sublingual tablets, patients receiving the injectable form reported significantly higher satisfaction and substantially lower treatment burden.18JAMA Network Open. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial For people who find daily dosing disruptive or stigmatizing, the injectable formulation can remove a meaningful obstacle to staying in treatment.
MOUD in the Criminal Justice System
People leaving incarceration face a staggering overdose risk. The period immediately after release is one of the most dangerous times in a person’s life because tolerance has dropped during months or years without opioid use. Programs that provide MOUD during incarceration and link people to treatment upon release address this directly.
A comprehensive correctional MOUD program found that out of 1,600 participants, only 12 died of overdose within a year of release, with just one of those deaths occurring in the particularly high-risk first two weeks. Previous research had found that 16% to 26% of post-release overdose deaths cluster in those first two weeks.19The Lancet Regional Health – Americas. Post-incarceration outcomes of a comprehensive statewide correctional MOUD program: a retrospective cohort study In a separate study of a prison buprenorphine program, all-cause mortality after release was lower than expected based on pre-implementation trends, while the rate of buprenorphine receipt after release roughly doubled.20JAMA Network Open. Prison Buprenorphine Implementation and Postrelease Opioid Use Disorder Outcomes These findings make a strong case for expanding MOUD access in jails and prisons, yet many correctional facilities still do not offer it.
Stigma as a Treatment Barrier
Perhaps the most stubborn obstacle to MOUD is not a policy or logistics problem but a cultural one. A widespread belief persists among both patients and treatment providers that taking methadone or buprenorphine is “just replacing one drug with another.” In one qualitative study, providers and people who use opioids frequently expressed this view, with many providers believing MOUD should be temporary and actively tapering patients off over time.21PubMed Central. “You’re Not Supposed to be on it Forever”: Medications to Treat Opioid Use Disorder (MOUD) Related Stigma Among Drug Treatment Providers and People who Use Opioids Providers also cited exaggerated fears of medication diversion as a reason not to prescribe.
A rapid review of barriers and facilitators found that stigma was the most common patient-level barrier, while logistical issues (time, cost, insurance requirements) were the most common provider-level barriers.22PubMed Central. Barriers and Facilitators to the Use of Medications for Opioid Use Disorder: a Rapid Review The combination creates a cycle: patients internalize shame about medication and encounter providers who reinforce it, leading many to avoid or leave treatment prematurely. Addressing this requires change not just in public attitudes but within the treatment workforce itself.
Policy Changes and the Prescribing Gap
For years, prescribing buprenorphine required a special federal waiver (the “X-waiver”) that limited which clinicians could prescribe and how many patients they could treat. In late 2022, Congress eliminated this requirement, meaning any practitioner with a DEA license can now prescribe buprenorphine for opioid use disorder. The hope was that this would dramatically expand access. The reality has been more complicated.
Research published before the change warned that physician interest in treating opioid use disorder was low across specialties, and that reluctance to prescribe had little to do with the X-waiver’s training requirements.23The Journal of the American Board of Family Medicine. The End of the X-waiver: Excitement, Apprehension, and Opportunity Early data bears this out. A study of state-level buprenorphine trends from 2018 through 2024 found that anticipated national increases in prescribing did not occur; state-level changes were highly variable, and the states that did see increases largely achieved them through expanded Medicaid prescribing.24PubMed Central. States With Substantial Increases In Buprenorphine Uptake Did So With Increased Medicaid Prescribing, 2018-24 Removing a regulatory hurdle is necessary but clearly not sufficient when the underlying barriers are attitudinal and structural.
Efforts to integrate MOUD into primary care have focused on giving practices the support infrastructure they need. One learning collaborative across multiple family medicine clinics found that the most consistent barrier was, again, stigma and its effects on staff willingness. Clinics that succeeded tended to have organizational leadership support, dedicated care teams, and residency programs enthusiastic about training in MOUD.25Family Medicine. Integrating MOUD and Primary Care: Outcomes of a Multicenter Learning Collaborative
Low-Threshold and Mobile Programs
One response to the access gap has been meeting people where they are, literally. Mobile medical units that park in neighborhoods with high overdose rates can offer buprenorphine on the spot, alongside wound care, vaccinations, and other services. A Chicago program using this model saw 587 unique patients in its first year, with buprenorphine initiation as the second most common reason for a first visit. About a third of buprenorphine patients returned for at least one follow-up.26Journal of Substance Use and Addiction Treatment. Outcomes of a mobile medical unit for low-threshold buprenorphine access targeting opioid overdose hot spots in Chicago These programs lower the barriers that clinic-based treatment inevitably creates: transportation, scheduling, paperwork, stigma associated with entering a treatment facility.
A related concern about mobile harm-reduction programs is community pushback, the worry that they attract crime or disorder. A study in the same city examined arrest patterns near mobile clinic locations and found the opposite. Total arrests within a mile of the clinics dropped by about a third compared to areas farther away, and drug arrests fell by a similar amount. The decline persisted even on days the clinics were not operating, suggesting a lasting stabilizing effect rather than just displacement.27PubMed. There goes the neighborhood? The public safety enhancing effects of a mobile harm reduction intervention
Adolescents and Young Adults
Young people with opioid use disorder face unique challenges accessing MOUD. A systematic review found that adolescents and young adults were consistently less likely than older populations to receive MOUD, and when they did, adolescents were more often given naltrexone or buprenorphine rather than methadone.28PubMed Central. Access to Medications for Opioid Use Disorder and Associated Factors Among Adolescents and Young Adults Qualitative research with young people described the experience of “chasing care,” struggling to find and maintain viable treatment connections. Participants said treatment success improved when programs addressed their basic needs like housing, transportation, and employment, and when providers communicated with authenticity rather than clinical detachment.29Pediatrics. Adolescent and Young Adult Access to Opioid Use Disorder Care
The Cost Argument
Beyond saving lives, MOUD reduces healthcare spending. A systematic review of economic evaluations found that patients receiving any form of MOUD used fewer healthcare resources and had lower total costs in the six months after treatment initiation compared with those who went untreated, roughly $10,000 versus $14,000 per patient in adjusted dollars.30PubMed Central. Economic Evaluations of Opioid Use Disorder Interventions: A Systematic Review Emergency department visits, hospitalizations, and incarceration all cost far more than a monthly prescription for buprenorphine or daily methadone dosing. The economic case for expanding MOUD access is straightforward.
How Other Countries Approach Access
The U.S. regulatory model for MOUD is unusually restrictive by international standards. A review of global approaches found that in France, liberal buprenorphine prescribing through primary care enabled rapid nationwide scale-up. In the U.K. and Australia, community pharmacy dispensing expanded reach without compromising safety. Portugal and Iran paired decriminalization with flexible, low-threshold public health models, and both saw reductions in overdose deaths. Russia, by contrast, prohibits MOUD entirely, and the consequences of that abstinence-only stance are visible in its overdose and HIV rates.31PubMed. Expanding Access to Buprenorphine and Methadone: Global Perspectives and Policy Recommendations Common regulatory bottlenecks identified across countries included daily supervised dosing requirements, restricted community prescribing, and drug scheduling that carries stigma. The international evidence suggests that loosening these constraints does not lead to the public safety harms opponents fear and can dramatically expand the number of people in treatment.